HomepageMedicinePharma Pulse 8/30/24: Working Towards Greater Access and Diversity, Why 'Normalcy' Is Still a Crisis & more Medicine Pharma Pulse 8/30/24: Working Towards Greater Access and Diversity, Why 'Normalcy' Is Still a Crisis & more admin Posted on September 1, 2024 The latest news for pharma industry insiders. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostMSN Realty, new venture by MSN Pharma promoters, to focus on Hyderabad real estate Next PostA Panorama of Design Products You Might Also Like Medicine Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases admin January 4, 2025 Medicine Aurlumyn Becomes First Severe Frostbite Medication to Receive FDA Approval admin February 15, 2024 Medicine Study Finds Association Between Neighborhood-Level Socioeconomic Status, Medication Nonadherence Among Heart Failure Patients admin December 20, 2023 Medicine Amylyx Pharmaceuticals Acquires Phase III-Ready GLP-1 Receptor Agonist Avexitide for Hyperinsulinemic Hypoglycemia from Eiger BioPharmaceuticals admin July 13, 2024
Medicine Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases admin January 4, 2025
Medicine Aurlumyn Becomes First Severe Frostbite Medication to Receive FDA Approval admin February 15, 2024
Medicine Study Finds Association Between Neighborhood-Level Socioeconomic Status, Medication Nonadherence Among Heart Failure Patients admin December 20, 2023
Medicine Amylyx Pharmaceuticals Acquires Phase III-Ready GLP-1 Receptor Agonist Avexitide for Hyperinsulinemic Hypoglycemia from Eiger BioPharmaceuticals admin July 13, 2024